The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Reckitt Benckiser announces a US$1bn plus new hit...and it is good news

By Chris Bailey | Thursday 11 July 2019

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

A month or so ago, I noted that Reckitt Benckiser (RB.) was a 'lower £60s buy in anticipation of a share price beginning with a '7' plus some solid dividend wrap-around...and a call option on that full split potential'. The rationale for this was not just the company's range of top products (VanishNurofenDettolDurex, etc.) nor even just potential upcoming split or a recently announced management evolution which I think is overdue. It was also centred on the likely resolution of the company's legacy problems with its ex pharmaceutical unit Indivior (INDV)...

You have reached premium content

You must be a paid subscriber to see this page.

Already a subscriber? Click here to sign in

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

Site by Everywhen